ST輔仁(600781.SH)收到上交所問詢函
格隆匯12月8日丨ST輔仁(600781.SH)發佈公告,2019年12月6日,公司收到上交所《關於對輔仁藥業集團製藥股份有限公司簽訂合作及技術轉讓協議有關事項的問詢函》(上證公函【2019】3054號)。
2019年12月6日,該公司發佈公告稱,公司子公司瑞輝與鄭州晟斯簽署了《合作協議》《技術轉讓協議》等。公告顯示,本次合作和轉讓所涉及的4個項目均未產生收益,並提示了相關事項尚存在較大不確定性的風險。根據上交所《股票上市規則》第17.1條的有關規定,請公司對相關事項進行回覆並補充披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.